Updates on the Management of Gastrointestinal Stromal Tumors

Surgical Oncology Clinics of North America

Volumn 21, Issue 2, 2012, Pages 301-316

  Bamboat, Zubin M ^a   DeMatteo, Ronald P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gastrointestinal stromal tumor; KIT; Surgery; Tyrosine kinase

Indexed keywords

DASATINIB; FLUORODEOXYGLUCOSE; IMATINIB; NILOTINIB; PLACEBO; SORAFENIB; SUNITINIB; VATALANIB;

ABDOMINAL PAIN; ARTIFICIAL EMBOLISM; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER RISK; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIARRHEA; DOG1 GENE; DRUG ERUPTION; DRUG TARGETING; DRUG TOLERABILITY; ENDOSCOPY; FATIGUE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE LOCUS; HISTOPATHOLOGY; HUMAN; IGFR1 GENE; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; LIVER TRANSPLANTATION; MUTATIONAL ANALYSIS; NAUSEA; ONCOGENE; ONCOGENE C KIT; OVERALL SURVIVAL; PDGFRALPHA GENE; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; REVIEW; SDH GENE; SKIN DISCOLORATION; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PEDIGREE; PIPERAZINES; PYRIMIDINES; RADIOTHERAPY, ADJUVANT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RISK ASSESSMENT;

EID: 84857377510     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2011.12.004     Document Type: Review

References (79)

1. Demetri G.D., Baker L.H., Benjamin R.S., et al. Soft tissue sarcoma. J Natl Compr Canc Netw 2007, 5(4):364-399.
2. Steigen S.E., Eide T.J. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS 2006, 114(3):192-200.
3. Tran T., Davila J.A., El-Serag H.B. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005, 100(1):162-168.
4. Prakash S., Sarran L., Socci N., et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 2005, 27(4):179-187.
5. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231(1):51-58.
6. Nishida T., Hirota S., Taniguchi M., et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998, 19(4):323-324.
7. Chompret A., Kannengiesser C., Barrois M., et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004, 126(1):318-321.
8. Takazawa Y., Sakurai S., Sakuma Y., et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 2005, 29(6):755-763.
9. Carney J.A. The triad of gastric epithelioid leiomyosarcoma, functioning extra-adrenal paraganglioma, and pulmonary chondroma. Cancer 1979, 43(1):374-382.
10. van der Zwan S.M., DeMatteo R.P. Gastrointestinal stromal tumor: 5 years later. Cancer 2005, 104(9):1781-1788.
11. Nilsson B., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005, 103(4):821-829.
12. Graadt van Roggen J.F., van Velthuysen M.L., Hogendoorn P.C. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001, 54(2):96-102.
13. Sepe P.S., Moparty B., Pitman M.B., et al. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc 2009, 70(2):254-261.
14. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33(5):459-465.
15. Miettinen M., Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005, 13(3):205-220.
16. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001, 61(22):8118-8121.
17. Antonescu C.R., Sommer G., Sarran L., et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003, 9(9):3329-3337.
18. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000, 156(3):791-795.
19. Chi P., Chen Y., Zhang L., et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010, 467(7317):849-853.
20. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299(5607):708-710.
21. Agaram N.P., Wong G.C., Guo T., et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008, 47(10):853-859.
22. Espinosa I., Lee C.H., Kim M.K., et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 2008, 32(2):210-218.
23. West R.B., Corless C.L., Chen X., et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004, 165(1):107-113.
24. Dematteo R.P., Gold J.S., Saran L., et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008, 112(3):608-615.
25. Franquemont D.W. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995, 103(1):41-47.
26. Martin J., Poveda A., Llombart-Bosch A., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005, 23(25):6190-6198.
27. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42(8):1093-1103.
28. Debiec-Rychter M., Wasag B., Stul M., et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004, 202(4):430-438.
29. Tarn C., Rink L., Merkel E., et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 2008, 105(24):8387-8392.
30. Janeway K.A., Kim S.Y., Lodish M., et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011, 108(1):314-318.
31. Rudolph P., Gloeckner K., Parwaresch R., et al. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study. Hum Pathol 1998, 29(8):791-800.
32. Ng E.H., Pollock R.E., Munsell M.F., et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992, 215(1):68-77.
33. Gunther T., Schneider-Stock R., Hackel C., et al. Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas. Clin Cancer Res 2000, 6(5):1811-1818.
34. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23(2):70-83.
35. Gold J.S., Gonen M., Gutierrez A., et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009, 10(11):1045-1052.
36. Lok K.H., Lai L., Yiu H.L., et al. Endosonographic surveillance of small gastrointestinal tumors originating from muscularis propria. J Gastrointestin Liver Dis 2009, 18(2):177-180.
37. Demetri G.D., von Mehren M., Antonescu C.R., et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010, 8(Suppl 2):S1-S41. [quiz: S2-4].
38. Karakousis G.C., Singer S., Zheng J., et al. Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison. Ann Surg Oncol 2011, 18(6):1599-1605.
39. Nishimura J., Nakajima K., Omori T., et al. Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection. Surg Endosc 2007, 21(6):875-878.
40. Dematteo R.P., Heinrich M.C., El-Rifai W.M., et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002, 33(5):466-477.
41. Edmonson J.H., Marks R.S., Buckner J.C., et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002, 20(5-6):605-612.
42. D'Amato G., Steinert D.M., McAuliffe J.C., et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005, 12(1):44-56.
43. Savage D.G., Antman K.H. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002, 346(9):683-693.
44. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347(7):472-480.
45. Dematteo RP, Owzar K, Antonescu CR, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000. In: American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium. Orlando (FL); 2008. p. A8.
46. Dematteo R.P., Ballman K.V., Antonescu C.R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373(9669):1097-1104.
47. Joensuu H. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial. J Clin Oncol 2011, 29(Suppl; abstract LBA1).
48. Hohenberger P., Oladeji O., Licht T., et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol 2009, 27(Suppl 1). [abstract: 10550].
49. Eisenberg B.L., Harris J., Blanke C.D., et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009, 99(1):42-47.
50. McAuliffe J.C., Hunt K.K., Lazar A.J., et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009, 16(4):910-919.
51. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344(14):1052-1056.
52. Katz S.C., DeMatteo R.P. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol 2008, 97(4):350-359.
53. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364(9440):1127-1134.
54. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008, 26(4):626-632.
55. (MetaGIST) GSTM-AG Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010, 28(7):1247-1253.
56. Van Glabbeke M., Verweij J., Casali P.G., et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 2006, 42(14):2277-2285.
57. Bumming P., Andersson J., Meis-Kindblom J.M., et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003, 89(3):460-464.
58. Bauer S., Hartmann J.T., de Wit M., et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005, 117(2):316-325.
59. DeMatteo R.P., Maki R.G., Singer S., et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007, 245(3):347-352.
60. Raut C.P., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006, 24(15):2325-2331.
61. Gronchi A., Fiore M., Miselli F., et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007, 245(3):341-346.
62. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26(4):620-625.
63. Kobayashi K., Szklaruk J., Trent J.C., et al. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors. Am J Clin Oncol 2009, 32(6):574-581.
64. Kobayashi K., Gupta S., Trent J.C., et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer 2006, 107(12):2833-2841.
65. Serralta A.S., Sanjuan F.R., Moya A.H., et al. Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol 2004, 16(11):1237-1239.
66. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25(13):1760-1764.
67. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25(13):1753-1759.
68. Chen L.L., Trent J.C., Wu E.F., et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004, 64(17):5913-5919.
69. Debiec-Rychter M., Cools J., Dumez H., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128(2):270-279.
70. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005, 11(11):4182-4190.
71. Prenen H., Cools J., Mentens N., et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006, 12(8):2622-2627.
72. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544):1329-1338.
73. Raut C.P., Wang Q., Manola J., et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol 2010, 17(2):407-415.
74. Joensuu H., De Braud F., Grignagni G., et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 2011, 104(11):1686-1690.
75. Wiebe L., Kasza K.E., Maki R.G., et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 2008, 26(Suppl 1). [abstract 10502].
76. Reichardt P., Montemurro M., Gelderblom H., et al. Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: a retrospective analysis. J Clin Oncol 2009, 27(Suppl 1). [abstract: 10564].
77. Antonescu C.R. Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models. Semin Diagn Pathol 2006, 23(2):63-69.
78. Kao J., Packer S., Vu H.L., et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009, 115(15):3571-3580.
79. Balachandran V.P., Cavnar M., Zeng S., et al. Imatinib mesylate potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of indoleamine 2,3-dioxygenase. Nat Med 2011, 17(9):1094-1100.